MedTrace Logo

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04859777 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2021-09-16

No results posted yet for this study

Summary

This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.

The study will be conducted in 3 parts:

* Part A: MPT-0118 dose-escalation
* Part B: MPT-0118 dose-escalation in combination with pembrolizumab
* Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab

Conditions

Interventions

DRUG

MPT-0118

MPT-0118 is an inhibitor of MALT1 protease

DRUG

MPT-0118 + pembrolizumab

MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor

Sponsors & Collaborators

  • Monopteros Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Arthur DeCillis, MD · Monopteros Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-13
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859777 on ClinicalTrials.gov